In Vitro Diagnostics (IVD) News: Breaking In Vitro Diagnostics (IVD) News, Comments and Articles. - Page: 5

20:40 EST 21st November 2014 | BioPortfolio

In Vitro Diagnostics (IVD) News - Page: 5Twitter RSS

Read the latest In Vitro Diagnostics (IVD) News from around the world, updated every five minutes. Breaking stories from leading news and press agencies, bloggers and experts on In Vitro Diagnostics (IVD).

Search or Follow Our In Vitro Diagnostics (IVD) - Page: 5 News…

If you are looking for more stories, you may wish to search our extensive news archives for relevant stories: Search for More In Vitro Diagnostics (IVD) - Page: 5 News.
You can also follow our In Vitro Diagnostics (IVD) - Page: 5 news stories on Twitter: @IVDiagnostics

Showing "invitro diagnostics vitro" News Articles 101 to 125 of 4,100+

Tuesday 18th November 2014

Valeant Picks Up Nicox's Diagnostics Unit

Valeant will pay up to $20 million to gain Nicox's diagnostics unit, including a panel for Sjögren’s syndrome and a lab-developed test for age-related macular degeneration.

GTG completes Australian genetics sale

Genetic Technologies (ASX:GTG) has completed the sale of its Australian genetics business to Specialist Diagnostics Services for $2 million.The sale to Primary Health Care’s pathology subsidiary forms part of Genetic Technologies’ strategy of divesting its non-core assets to focus on the US molecular diagnostics market and commercialisation of flagship breast cancer risk assessment tool BREVAG...

Kadmon Corporation Presents Preclinical Data on Bi-Functional Anti-PD-L1/IL-15 Fusion Protein at EORTC-NCI-AACR Symposium

NEW YORK, NY -- (Marketwired) -- 11/19/14 -- Kadmon Corporation, LLC, today announced the presentation of preclinical data demonstrating the potential of a novel, bi-functional anti-PD-L1/IL-15 fusion protein, KD033, for the treatment of cancer. The data were presented in a poster session at the 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, taking place in Barcelona,...

The Association for Molecular Pathology announces 2014 award recipients

(Association for Molecular Pathology) The Association for Molecular Pathology announced its 2014 award winners. Recipients of the Award for Excellence in Molecular Diagnostics, Jeffrey A. Kant Leadership Award, and AMP Meritorious Service Award were ...

Seegene Receives US Patent for TOCE(TM) Technology

GAITHERSBURG, MD and SEOUL, KOREA -- (Marketwired) -- 11/19/14 -- Seegene Inc. (KOSDAQ: 096530), a leading developer of multiplex PCR technologies, today announced that it has been issued a United States Patent, No. 8,809,239, for its tagging oligonucleotide capture and extension (TOCE™) technology, which enables highly multiplexed target amplification and detection in a single tube. TOCE™ tec...

Pharmaceutical Research: Thermosensitive Liposome Formulated Indocyanine Green for Near-Infrared Triggered Photodynamic Therapy: In Vivo Evaluation for Triple-Negative Breast Cancer

Type: Original PaperPurposeThe focus of this research was to formulate and evaluate a theranostic liposomal delivery system using indocyanine green (ICG) as a photosensitizer, triggered by near infrared (NIR) irradiation, for in vivo photodynamic the...

Pharmaceutical Research: Bridging Laboratory and Large Scale Production: Preparation and In Vitro-Evaluation of Photosensitizer-Loaded Nanocarrier Devices for Targeted Drug Delivery

Type: Original PaperPurposeIndustrial production of nanosized drug delivery devices is still an obstacle to the commercialization of nanomedicines. This study encompasses the development of nanoparticles for peroral application in photodynamic therap...

Pharmaceutical Research: In Silico Prediction of Percutaneous Absorption and Disposition Kinetics of Chemicals

Type: Original PaperPurposeTo develop in-silico model for predicting percutaneous absorption and disposition kinetics of chemicals in skin layers so as to facilitate the design of transdermal drug delivery systems and skin care products, and risk ass...

Ignyta Announces RXDX-101 Presentations at the 2014 EORTC-NCI-AACR ‘Molecular Targets and Cancer Therapeutics’ Conference

Ignyta, Inc. (Nasdaq: RXDX), a precision oncology biotechnology company, today announced the acceptance of two abstracts for poster presentations relating to RXDX-101, the company’s proprietary oral tyrosine kinase inhibitor targeting solid tumor indications, at the 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. The poster p...

Shimadzu’s UV-3600 Plus UV-VIS-NIR Spectrophotometer Offers High-Sensitivity, High-Resolution Analyses for a Wide Range of Applications

The UV-3600 Plus offers high-resolution analysis in the following application areas: materials science, including photovoltaics, electronics, optical coatings, and textiles; food science; pharmaceuticals, cosmetics and life sciences; and chemicals. COLUMBIA, Md. (PRWEB) November 18, 2014 Incorporating the latest technology to achieve high sensitivity, high resolution and an ultra-low stray light ...

Vermillion Outlines Expanded Strategic Mission; Forms New Strategic & Medical Advisory Board

AUSTIN, Texas, Nov. 18, 2014 /PRNewswire/ -- Vermillion, Inc. (NASDAQ: VRML), a bio-analytical solutions company focused on gynecologic disease, recently outlined its expanded strategy for driving improvements in the personalized management of gynecologic health and becoming the leading diagnostic innovator in gynecologic informatics. In support of this mission, the Company is naming three charter...

Genetic Analysis grants Rebiotix rights to GA-map

Molecular diagnostics firm Genetic Analysis AS granted Rebiotix Inc. (focusing on gastrointestinal diseases) access to its CE-marked GA-map test for dysbiosis, a microbial imbalance of the digestive tract.

Capnia, Inc. Announces Closing of Initial Public Offering and Partial Exercise of Over-Allotment Option

REDWOOD CITY, Calif., Nov. 18, 2014 /PRNewswire/ -- Capnia, Inc. (NASDAQ: CAPN) announced today the closing of its initial public offering of 1,650,000 units, each unit consisting of one share of common stock, one Series A warrant to purchase one share of common stock and one Series B warrant to purchase one share of common stock, at a price to the public of $6.50 per unit. In addition, the Compan...

Alere to Participate in Jefferies Global Healthcare Conference

WALTHAM, Mass., Nov. 18, 2014 /PRNewswire/ -- Alere Inc. (NYSE: ALR), a global leader in rapid diagnostic tests, announced that it will participate in the Jefferies Global Healthcare investment conference to be held on November 19-20, 2014 at the Waldorf Hilton in London. Jon Russell, Vice President, Finance, will present at the conference on Thursday, November 20, 2014 at 8:40 am GMT. An Al...

HelomicsTM to Be Recognized at the 2014 Pittsburgh Smart 50 Awards

Helomics (formerly Precision Therapeutics), a privately held comprehensive personalized healthcare company that develops innovative next generation diagnostics for the oncology field, announced today that it will be recognized as a recipient of the 2014 Pittsburgh Smart 50 Awards, presented by Chase and Smart Business. President and CEO Neil Campbell will ...

Definiens Predicts Biggest Drivers for Personalized Medicine in 2015: Data Quality, Immunotherapy, Combination Treatments and Predictive Biomarkers

Big Opportunities Exist for Cancer Research and Treatment, But Challenges Ahead Major opportunities are on the horizon for personalized medicine and clinical cancer research and treatment, according to Definiens, the global leader in Tissue Phenomics® for oncology diagnostics. The company predicts that the biggest trends driving the industry over the ...

Zoetis acquires Abbott animal health assets

Zoetis announced an agreement to purchase animal health assets of Abbott for a purchase price of $255 million. Abbott Animal Health is a companion animal health business focused on the veterinary surgical suite. This acquisition will strengthen Zoetis’ companion animal product portfolio and expand its diagnostics business as more pets are being treated for pain more » The post Zoetis acquires A...

Rosetta Genomics and Marina Biotech Initiate First Clinical Project Under Strategic Alliance / Clinical Study Intended to Identify Novel microRNA Candidates for the Treatment of Duchenne Muscular Dystrophy

PRINCETON, NJ and REHOVOT, ISRAEL and BOTHELL, WA -- (Marketwired) -- 11/18/14 -- Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics and...

Temperature monitoring of frozen embryos, sperm and ova

Infertility is a growing problem, not only in Australia, but around the world. According to IVF Australia, 15% of couples of reproductive age are affected by infertility because of either genetic, medical or surgical reasons where the cause remains unknown. Fortunately, technology has improved significantly in recent years and has allowed in-vitro fertilisation (IVF) to become an efficient way of ...

Genetic Signatures launches prospectus for IPO

Australian molecular diagnostics company Genetic Signatures has launched a prospectus for its upcoming IPO. The Sydney-based company plans to list on the ASX on 23 December and is seeking to attract the interest of institutional and retail investors. The company plans to use the funds raised from the listing to help support the expansion of its customer base and product lines. “The procee...

Development of Integrated Diagnostic Servers by Pathology and Radiology

I have posted a number of previous notes about integrated diagnostics and integrated diagnostic centers (see: Integrated Diagnostics and Its Relationship to Digital Pathology: A Strategic Analysis; Revisiting Integrated Diagnostics and the Integrated...

Precision For Medicine Launches New Business Units Focused On Demonstrating Product Value And Supporting Commercial Excellence

BETHESDA, Md., Nov. 18, 2014 /PRNewswire/ -- Precision for Medicine, Inc., formed in 2012 to support next-generation approaches to drug development and commercialization, announces the launch of a new strategic business unit and adjacent global life sciences consulting firm focused directly on the demonstration of product value. The solutions, Precision for Value and Precision Advisors, will ...

AACC Joins AMA, Other Major Healthcare Organizations Urging FDA to Withdraw Its Proposed Framework for Laboratory Developed Tests; Proposal Could Jeopardize Patient Access to Critical Testing Services

WASHINGTON, Nov. 18, 2014 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration (FDA) issued its long-awaited proposal on October 3 for overseeing laboratory developed tests—medical tests that are created and used within a single lab, and often developed to fulfill unmet clinical needs. AACC is concerned that this guidance could hinder the ability of labs to provide physicians wit...

Harbor Health Systems Launches Care Concierge Services Prior to 2015 Implementation Deadline

Outcome-driven Care Management Service Connects Injured Workers with Best Doctors and Ancillary Services Harbor Health Systems now offers a new solution to assist injured workers in moving through the continuum of care efficiently, achieving faster return-to-work at a lower overall cost.

ACLA Retains Attorneys Paul D. Clement and Laurence H. Tribe To Represent ACLA in Opposing the FDA's Proposal To Treat Laboratory Developed Tests (LDTs) as Medical Devices

WASHINGTON, Nov. 18, 2014 /PRNewswire-USNewswire/ -- The American Clinical Laboratory Association (ACLA) announced today that it has retained former Solicitor General Paul D. Clement, a partner with Bancroft PLLC, and Laurence H. Tribe, the Carl. M. Loeb University Professor and Professor of Constitutional Law at Harvard University, and a distinguished scholar working with Massey & Gail L...


Search BioPortfolio:
Loading
Advertisement
Advertisement

News Quicklinks